The University of Southampton
University of Southampton Institutional Repository

An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer.

Powles, Thomas, Sarwar, Naveed, Jones, Rob, Wilson, Peter, Boleti, Ekaterini, Protheroe, Andrew, Crabb, Simon J, Shamash, Jonathan, Stockdale, Andrew, Rashid, Sukaina, Nathan, Paul and Chowdury, Simon (2012) An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer. European Journal of Cancer (doi:10.1016/j.ejca.2012.05.022). (PMID:22766517).

Record type: Article


Background: both sunitinib and pazopanib are widely used as first line therapy in metastatic renal cancer (mRCC). The efficacy of these agents appears similar but they may have distinct toxicity profiles. In this study we compare the severity of symptomatic and asymptomatic toxicity associated with sunitinib and pazopanib.

Methods: two sequential prospective single arm phase II studies investigated either 12weeks of sunitinib (n=43) or pazopanib (n=34) prior to nephrectomy in untreated mRCC. Toxicity was defined as either symptomatic (hand and foot syndrome, mucositis, nausea, fatigue, diarrhoea, oedema, headache, pain, anorexia and change in taste) or asymptomatic (liver toxicity or haematological toxicity). Pazopanib (800mg once daily (OD)) and sunitinib (50mg 4/2) were given. Regular Common Toxicity Criteria (CTC) toxicity assessment was performed during the first 12weeks of therapy.

Results: there was no significant difference in the overall number of toxic events (grade 1-4) for sunitinib and pazopanib (mean number of toxic events/patients: 1.97 versus 1.96: p>0.05). Increased grade 2-4 symptomatic toxicity events occurred with sunitinib (hazard ratio (HR) 1.67 [95% confidence interval (CI): 1.11-2.56] p<0.03). Sunitinib was associated with an increased grade 2-4 mucositis (16% versus 0% p=0.02) and fatigue (42% versus 15% p=0.01). Pazopanib was associated with more frequent grade 1 diarrhoea (39% versus 12%: p=0.03). Dose reductions for symptomatic toxicity occurred more frequently with sunitinib (26% versus 6% p<0.05). There was no difference in the occurrence of asymptomatic toxicity.

Conclusion: this indirect analysis suggests sunitinib and pazopanib have distinct toxicity profiles which may help guide patient's choice. Further comparative data from randomised trials are awaited.

Full text not available from this repository.

More information

e-pub ahead of print date: 3 July 2012
Organisations: Cancer Sciences


Local EPrints ID: 342454
ISSN: 0959-8049
PURE UUID: 5075d57b-87fd-4646-a1fa-f0ba85b37ad4

Catalogue record

Date deposited: 30 Aug 2012 09:27
Last modified: 18 Jul 2017 05:28

Export record



Author: Thomas Powles
Author: Naveed Sarwar
Author: Rob Jones
Author: Peter Wilson
Author: Ekaterini Boleti
Author: Andrew Protheroe
Author: Simon J Crabb
Author: Jonathan Shamash
Author: Andrew Stockdale
Author: Sukaina Rashid
Author: Paul Nathan
Author: Simon Chowdury

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton:

ePrints Soton supports OAI 2.0 with a base URL of

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.